Diabetes insipidus related to sedation in the intensive care unit: A review of the literature

Kraus, Molly B; Leuzinger, Kahlin; Reynolds, Emily G.; Moraes, Alice Gallo De; Smith, JuliAnna Z.; Sharpe, Emily E.; Quillen, Jaxon; Kosiorek, Heidi E.; Harbell, Monica W.

doi:10.1016/j.jcrc.2022.154233

Cited by 4 publications

(1 citation statement)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…And notably, our study found that endocrine system disorders also have high-intensity signals, such as diabetes insipidus. In line with existing literature ( Kraus et al, 2023 ), dexmedetomidine is frequently implicated in sedation-related diabetes insipidus in critically ill ICU patients. Potential mechanisms include dexmedetomidine’s reduction of central arginine vasopressin (AVP) release and diminished renal response to AVP in canine and rat models ( Rouch and Kudo, 1996 ; Kudo et al, 1999 ; Villela et al, 2005 ).…”

Section: Discussionsupporting

confidence: 85%

Clinical adverse events to dexmedetomidine: a real-world drug safety study based on the FAERS database

Liu,

Zheng,

2024

Front. Pharmacol.

View full text Add to dashboard Cite

ObjectiveAdverse events associated with dexmedetomidine were analyzed using data from the FDA’s FAERS database, spanning from 2004 to the third quarter of 2023. This analysis serves as a foundation for monitoring dexmedetomidine’s safety in clinical applications.MethodsData on adverse events associated with dexmedetomidine were standardized and analyzed to identify clinical adverse events closely linked to its use. This analysis employed various signal quantification analysis algorithms, including Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-Item Gamma Poisson Shrinker (MGPS).ResultsIn the FAERS database, dexmedetomidine was identified as the primary suspect in 1,910 adverse events. Our analysis encompassed 26 organ system levels, from which we selected 346 relevant Preferred Terms (PTs) for further examination. Notably, adverse drug reactions such as diabetes insipidus, abnormal transcranial electrical motor evoked potential monitoring, acute motor axonal neuropathy, and trigeminal cardiac reflex were identified. These reactions are not explicitly mentioned in the drug’s specification, indicating the emergence of new signals for adverse drug reactions.ConclusionData mining in the FAERS database has elucidated the characteristics of dexmedetomidine-related adverse drug reactions. This analysis enhances our understanding of dexmedetomidine’s drug safety, aids in the clinical management of pharmacovigilance studies, and offers valuable insights for refining drug-use protocols.

show abstract